Drug Modulators of B Cell Signaling Pathways and Epstein-Barr Virus Lytic Activation.

Item

http://www.wikidata.org/entity/Q40178497

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Drug Modulators of B Cell Signaling Pathways and Epstein-Barr Virus Lytic Activation.

@en

type

Item

label

Drug Modulators of B Cell Signaling Pathways and Epstein-Barr Virus Lytic Activation.

@en

prefLabel

Drug Modulators of B Cell Signaling Pathways and Epstein-Barr Virus Lytic Activation.

@en

P1476

Drug Modulators of B Cell Signaling Pathways and Epstein-Barr Virus Lytic Activation.

@en

P2093

Brandon Peiffer

http://www.w3.org/2001/XMLSchema#string

Gangling Liao

http://www.w3.org/2001/XMLSchema#string

Jaeyeun Lee

http://www.w3.org/2001/XMLSchema#string

Jianmeng Chen

http://www.w3.org/2001/XMLSchema#string

John G Kosowicz

http://www.w3.org/2001/XMLSchema#string

Jun O Liu

http://www.w3.org/2001/XMLSchema#string

Richard F Ambinder

http://www.w3.org/2001/XMLSchema#string

S Diane Hayward

http://www.w3.org/2001/XMLSchema#string

Zufeng Guo

http://www.w3.org/2001/XMLSchema#string

P2860

X-Linked agammaglobulinemia patients are not infected with Epstein-Barr virus: implications for the biology of the virus.

Rapamycin ameliorates the CTLA4-Ig-mediated defect in CD8(+) T cell immunity during gammaherpesvirus infection.

Epstein-Barr virus gH is essential for penetration of B cells but also plays a role in attachment of virus to epithelial cells.

A simple and efficient route to the FKBP-binding domain from rapamycin

Ibrutinib (PCI-32765), the first BTK (Bruton's tyrosine kinase) inhibitor in clinical trials

Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110δ result in T cell senescence and human immunodeficiency

A calcineurin-independent mechanism of angiogenesis inhibition by a nonimmunosuppressive cyclosporin A analog.

High Viral Loads of Epstein-Barr Virus DNA in Peripheral Blood of Patients with Chronic Lymphocytic Leukemia Associated with Unfavorable Prognosis.

Dasatinib therapy results in decreased B cell proliferation, splenomegaly, and tumor growth in a murine model of lymphoma expressing Myc and Epstein-Barr virus LMP2A.

Prognostic impact of Epstein-Barr virus (EBV)-DNA copy number at diagnosis in chronic lymphocytic leukemia.

P31

scholarly article

P356

10.1128/JVI.00747-17

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-05-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28566383

http://www.w3.org/2001/XMLSchema#string

P921

Epstein–Barr virus

P932

5533897

http://www.w3.org/2001/XMLSchema#string